Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates accelerated diabetic wound healing using an enzymatic albumin hydrogel, indicating cross-scale redox regulation benefits.
Artificial skin substitutes and hydrogel dressings have improved diabetic wound care by providing coverage, moist interfaces, and structural support for re-epithelialization. However, many current systems still show limited long-term retention and insufficient active remodeling of the hostile diabetic wound microenvironment, where ROS-driven oxidative stress serves as a key node sustaining chronic nonhealing. Here, we report BTSC, a dynamic skin-mimetic albumin hydrogel designed as a wound-retentive artificial protein skin with an embedded mitochondria-targeted bioenzymatic cascade module for cross-scale redox repair. The albumin network acts as a bioactive protein matrix rather than a passive scaffold, integrating injectability, self-healing, wet adhesion, skin-like mechanical compatibility, tissue-level ROS buffering, and stabilization of mitochondria-targeted SOD/CAT nanocomposites (TPP-SC). In the acidic diabetic wound microenvironment, Schiff base crosslinks enabled sustained pH-responsive TPP-SC release over approximately one week. During local retention, BTSC buffered wound-bed ROS and supported SOD/CAT-mediated O 2 generation from endogenous H 2 O 2 , mitigating oxidative and hypoxic stress. Released TPP-SC further accumulated in mitochondria, attenuated mtROS, and helped restore mitochondrial redox balance. This tissue-to-organelle redox regulation reduced inflammation, promoted angiogenesis, collagen remodeling, and re-epithelialization, and accelerated diabetic wound closure.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: